The Incidence of Pulmonary, Cardiovascular and Renal System Non-communicable Complications Associated With the Post-acute Phase of the Infection by Covid-19 (POINT)

November 14, 2025 updated by: Hellenic Institute for the Study of Sepsis

A Non-interventional, Prospective, Cross-sectional Study of the Incidence of Pulmonary, Cardiovascular and Renal System Non-communicable Complications Associated With the Post-acute Phase of the Infection by Sars-Cov-2

More than 660 million cases of COVID-19 have been reported worldwide, with 183 million cases in the EU alone. In several people, after recovery, the effects of the first waves of COVID-19 persisted beyond the acute phase and increased the risk of chronic multiorgan symptoms and disease. Up to 70% of people affected by COVID-19 showed reduced organ function even four months or more after COVID-19 diagnosis. Such a functional decline is associated with an increased risk of the development of non-communicable diseases (NCDs). Thus, there is an essential need for a better knowledge, tools, clinical guidelines and recommendations that it will make it possible to reduce this overrepresentation of NCDs as a consequence of the post-acute phase (PAP) of COVID-19.

The overall concept underpinning "POINT" is to i) build detailed knowledge on the link between the PAP of COVID-19 caused by previous, current, and future SARS-CoV-2 variants in vaccinated and unvaccinated people, and NCDs, ii) identify robust biomarkers and build predictive tools that help early identification and management of risk of NCDs, and iii) develop guidelines and recommendations for all parts of the healthcare value chain, allowing best prevention and care acknowledging vulnerability. The investigators will focus on the NCDs affecting pulmonary, cardiovascular and renal systems.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Post-acute phase of COVID and Non-communicable diseases

Following the emergence of SARS-CoV-2, more than 660 million cases of COVID-19 have been reported worldwide, with 183 million cases in the EU alone. These numbers will continue to grow even after the disease becomes endemic. In some people, after recovery, the effects of the first waves of COVID-19 persisted beyond the acute phase and increased the risk of chronic multiorgan symptoms and disease. Up to 70% of people affected by COVID-19 showed reduced organ function even four months or more after COVID-19 diagnosis. Such a functional decline is associated with an increased risk of the development of non-communicable diseases (NCDs). This is especially true for individuals aged 65 and older as the risk of NCDs increases with age.

Diseases of the pulmonary, cardiovascular, and renal systems are the three major NCDs carrying the most significant burden for the individual as well as society. Studies have documented compromised function of these 3 organ systems in the PAP of COVID-19 in 30%-70% of patients, regardless of the severity of the acute-phase. As homeostasis of these three organs depends on interorgan communication with each other, the impact of PAP of COVID-19 on one will impact the others. The added stress of the PAP of COVID-19 increases the risk of a higher incidence and/or the risk of an accelerated progression of disease.

The prevalence and socioeconomic cost of the three NCDs is already extremely high. Without a strong focus on minimmising the increased risk of incidence and accelerated progression of the NCDs as a result of the PAP of COVID-19, up to 9 million Europeans may be affected and result in an added direct attributable cost of between 19.564 € - 31.064 € per year for each person who develop an NCD.

Beyond state of the art: pulmonary, cardiovascular and renal complications after the PAP of COVID-19

Post-acute COVID-19 and pulmonary complications - Respiratory conditions have been reported as occurring twice as often after severe COVID-19 as in the general population. In a study of 135 individuals, the incidence of impaired lung diffusing capacity (DLCO) and persistent lung damage was demonstrated in 30% of patients 12 months after acute COVID-19. In another study of 142 individuals, pulmonary abnormalities were observed by CT scans in 54% of individuals a year after acute COVID-19.

Post-acute COVID-19 and cardiovascular complications - The PAP of COVID-19 is associated with an increased risk of deep vein thrombosis up to three months after COVID-19 infection, pulmonary embolism up to six months, and a bleeding event up to two months. In a registry study of 153,760 individuals with COVID-19, the 12 month period following the acute phase was characterized by an increased risk and an excess disease burden of cardiovascular diseases, including heart failure, dysrhythmias and stroke. The risks were evident regardless of age, race, sex, and other cardiovascular risk factors. MRI revealed cardiac impairment in 78% of 100 individuals in the PAP of COVID-19.

Post-acute COVID-19 and renal complications - A study of 1733 individuals documented reduced renal function in 35% 6 months after the acute phase of COVID-19 and 13% of patients who did not have acute kidney injury (AKI) during the acute phase showed a disproportionate reduction in renal function during follow-up. A study including >89,000 individuals revealed an increased risk of adverse renal outcomes in the PAP of COVID-19.

The main unmet needs requiring action at the European level There is an urgent need to enable a better understanding of the causality between PAP of COVID-19 and the increased risk of pulmonary, cardiovascular, and renal complications and thereby an increased risk of onset of disease or aggravation of existing disease. Even though recent studies suggest such a link, there is a need for a more nuanced study of the correlation on much larger cohorts to determine the incidence and risk ratio more accurately. Furthermore, there is a need to compare the outcomes between the early, present, and potential future strains of SARS-CoV-2 variants responsible for the disease. An increased cohort size will also allow a better understanding of the impact of socioeconomic status, difference between sexes, the compounding effects of genotype, pre-existing comorbidities, and use of prescription drugs and of differences between the PAP of early strains of SARS-CoV-2 in mostly unvaccinated individuals compared with current strains in mostly vaccinated people. As this knowledge is currently incomplete, there is an immediate risk that a large part of the European population will not receive optimal and timely care.

Thus far, investigators have concluded that the functional decline of organs caused by COVID-19 cannot be explained by known risk factors. A review of the recent literature suggests that the PAP of COVID-19 is associated with immune dysregulation, elevated levels of autoantibodies, microbiota disruption and clotting and endothelial abnormalities. However, the same review also concludes that the current understanding is not sufficient to improve outcomes and calls for additional research. This underscores the involvement of unidentified molecular mechanisms responsible for the aetiology. A lack of understanding of these inhibits the development of effective biomarkers and drug candidates that allow optimal prediction of the prognosis and treatment of patients following resolution of the initial symptoms of COVID-19.

There is an urgent need for updated clinical practice guidelines and new tools to diagnose and prevent the development and aggravation of NCDs caused by the PAP of COVID-19. Currently, there are very few clinical guidelines and recommendations related to the PAP of COVID-19 and NCDs in general, and there are even fewer clinical guidelines and recommendations that focus on the effects of the PAP of COVID-19 on pulmonary, cardiovascular, and renal health. Modern clinical practice guidelines and recommendations that efficiently bridge the gap between research and current practice are invaluable for securing best quality of care, patient outcomes and cost effectiveness. Unfortunately, the development of a guideline or a recommendation does not necessarily lead to changes in clinical practice. Clinical guidelines and recommendations are not always followed, and it is estimated that approximately 30%-40% of patients receive treatment that is not based on scientific evidence and 20%-25% receive treatments that are not needed or potentially harmful.

Study Type

Observational

Enrollment (Estimated)

345

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Prof. Evangelos Giamarellos-Bourboulis
  • Phone Number: 00302105831994
  • Email: egiamarel@med.uoa.gr

Study Locations

  • Greece
      • Athens, Greece
        • Recruiting
        • 4th Department of Internal Medicine, ATTIKON University General Hospital
        • Contact:
      • Athens, Greece
        • Recruiting
        • Out-patient department of Infectious Diseases, Sotiria Athens Hospital of Chest Diseases
        • Contact:
      • Athens, Greece
        • Recruiting
        • Obstructive Diseases Clinic, Sotiria Athens Hospital of Chest Diseases
        • Contact:
      • Athens, Greece
        • Recruiting
        • 10th Department of Pulmonary Medicine, Sotiria Athens Hospital of Chest Diseases
        • Contact:
      • Elefsina, Greece
        • Recruiting
        • 1st Department of Internal Medicine, Thriasio General Hospital of Elefsina
        • Contact:
      • Elefsina, Greece
        • Recruiting
        • 2nd Department of Internal Medicine, Thriasio General Hospital of Elefsina
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Probability Sample

Study Population

POINT will include patients who have participated in the studies ESCAPE, SAVE, SAVE-MORE and SAVE-LONG. For these patients blood samples and clinical data are already available (Baseline - Year 0 from ESCAPE, SAVE & SAVE-MORE and Year 1 from SAVE-LONG).

POINT needs to enroll three groups of patients (selected by the existing biobank mentioned above, based on the inclusion and exclusion study criteria) to cover the magnitude of the spectrum of COVID-19:

  • Group A (115 Comparators): Comparators without medical history of acute infection by SARS-CoV-2.
  • Group B (115 with NO dysfunction): Patients fully recovered by acute COVID-19 who did not present any acute organ injury during acute infection by SARS-CoV-2.
  • Group C (115 with Dysfunctions): Patients who presented signs of lung, heart, and kidney dysfunction during acute infection by SARS-CoV-2.

Description

Inclusion Criteria:

Group A (comparators)

  1. Adults (18 years or more) of both genders
  2. Negative history of acute COVID-19

Group B (patients with ΝΟ dysfunction)

  1. Adults (18 years or more) of both genders
  2. History of acute COVID-19 hospitalized or non-hospitalized. All cases appearing from start of the pandemic until the last six months may apply
  3. Absence of any current overt organ dysfunction
  4. Absence of signs of any organ dysfunction during acute COVID-19

Group C (patients with dysfunctions)

  1. Adults (18 years or more) of both genders
  2. History of acute COVID-19 hospitalized or non-hospitalized. All cases appearing from start of the pandemic until the last six months may apply
  3. Presence of signs of organ dysfunction of the lung, the kidneys or the heart during acute COVID-19

Exclusion Criteria:

Group A (comparators)

  1. Any other co-existing disorder generating clinical symptoms
  2. Failure to thrive according to the attending physicians
  3. Pregnancy or lactation

Group B (patients with ΝΟ dysfunction)

  1. Any other co-existing disorder generating clinical symptoms
  2. Failure to thrive according to the attending physicians
  3. Pregnancy or lactation

Group C (patients with dysfunctions)

  1. Any other co-existing disorder generating clinical symptoms

  2. Medical history of any of:

    • stage III or IV chronic obstructive pulmonary disease according to the GOLD criteria
    • pulmonary fibrosis or pulmonary hypertension
    • stage IV solid tumour malignancy under chemotherapy or radiotherapy
    • systemic sclerosis
    • congestive heart failure
    • stage II, III or IV dyspnoea according to the New York Heart Association classification before the acute COVID-19
  3. Limited chance of survival for at least six months due to co-existing comorbidity(-ies) according to the judgement of the attending physicians
  4. Pregnancy or lactation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Comparators
Comparators without medical history of acute infection by SARS-CoV-2.
Other: Blood samples
Blood sampling for proteomics and transcriptomics, suPAR measurement & isolation and stimulation of peripheral blood mononuclear cells, eGFR, serum creatinine, cystatin c & urea
Other: Six-minute walk test, Spirometry, HRCT, Heart ultrasound, Completion of questionnaires of symptoms
Spirometry for forced expiratory volume in the first, second, total lung capacity and diffusion capacity of carbon monoxide.
Participants with NO dysfunction
Patients fully recovered by acute COVID-19 who did not present any acute organ injury during acute infection by SARS-CoV-2.
Other: Blood samples
Blood sampling for proteomics and transcriptomics, suPAR measurement & isolation and stimulation of peripheral blood mononuclear cells, eGFR, serum creatinine, cystatin c & urea
Other: Six-minute walk test, Spirometry, HRCT, Heart ultrasound, Completion of questionnaires of symptoms
Spirometry for forced expiratory volume in the first, second, total lung capacity and diffusion capacity of carbon monoxide.
Participants with Dysfunctions
Patients who presented signs of lung, heart, and kidney dysfunction during acute infection by SARS-CoV-2.
Other: Blood samples
Blood sampling for proteomics and transcriptomics, suPAR measurement & isolation and stimulation of peripheral blood mononuclear cells, eGFR, serum creatinine, cystatin c & urea
Other: Six-minute walk test, Spirometry, HRCT, Heart ultrasound, Completion of questionnaires of symptoms
Spirometry for forced expiratory volume in the first, second, total lung capacity and diffusion capacity of carbon monoxide.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The incidence of any organ dysfunction during the first 48 months among patients of group C compared to group B
Time Frame: From enrollment to Month 48
This is a composite endpoint which includes the development of chronic failures of at least one of lung, heart and/or kidneys
From enrollment to Month 48

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The incidence of any organ dysfunction during the first 48 months among patients of group C compared to group A.
Time Frame: From enrollment to Month 48.
This is a composite endpoint which includes the development of chronic failures of at least one of lung, heart and/or kidneys.
From enrollment to Month 48.
The incidence of any organ dysfunction during the first 48 months among patients of group B compared to group A.
Time Frame: From enrollment to Month 48.
This is a composite endpoint which includes the development of chronic failures of at least one of lung, heart and/or kidneys.
From enrollment to Month 48.
The incidence of chronic lung failure during the first 48 months among patients of group C compared to group B.
Time Frame: From enrollment to Month 48.
From enrollment to Month 48.
• The incidence of chronic heart failure during the first 48 months among patients of group C compared to group B.
Time Frame: From enrollment to Month 48.
From enrollment to Month 48.
• The incidence of chronic renal disease during the first 48 months among patients of group C compared to group B.
Time Frame: From enrollment to Month 48.
From enrollment to Month 48.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hellenic Institute for the Study of Sepsis

Investigators

  • Study Chair: Prof. Evangelos Giamarellos-Bourboulis, Hellenic Institute for the Study of Sepsis

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 10, 2024

Primary Completion (Estimated)

November 4, 2027

Study Completion (Estimated)

November 4, 2027

Study Registration Dates

First Submitted

September 17, 2024

First Submitted That Met QC Criteria

September 20, 2024

First Posted (Actual)

September 23, 2024

Study Record Updates

Last Update Posted (Actual)

November 17, 2025

Last Update Submitted That Met QC Criteria

November 14, 2025

Last Verified

November 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • POINT

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on COVID-19

Clinical Trials on Blood samples

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cyprus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe